Anbio Biotechnology Class A Ordinary Shares - Asset Resilience Ratio
Anbio Biotechnology Class A Ordinary Shares (NNNN) has an Asset Resilience Ratio of 13.67% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Anbio Biotechnology Class A Ordinary Sha short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Anbio Biotechnology Class A Ordinary Shares's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see NNNN total asset value.
Liquid Assets Composition Over Time
This chart breaks down Anbio Biotechnology Class A Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read NNNN liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.13 Million | 13.67% |
| Total Liquid Assets | $4.13 Million | 13.67% |
Asset Resilience Insights
- Moderate Liquidity: Anbio Biotechnology Class A Ordinary Shares has 13.67% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Anbio Biotechnology Class A Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Anbio Biotechnology Class A Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.87% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Autek China Inc
SHE:300595 |
Medical Instruments & Supplies | 21.20% |
|
Jiangxi Sanxin Medtec Co Ltd
SHE:300453 |
Medical Instruments & Supplies | 13.70% |
|
QITIAN Technology Group Co Ltd
SHE:300061 |
Medical Instruments & Supplies | 0.00% |
|
Dentium
KO:145720 |
Medical Instruments & Supplies | 1.23% |
|
Interojo Inc
KQ:119610 |
Medical Instruments & Supplies | 6.55% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
Annual Asset Resilience Ratio for Anbio Biotechnology Class A Ordinary Shares (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Anbio Biotechnology Class A Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.67% | $4.13 Million | $30.24 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $18.92 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $15.81 Million | -- |
| 2022-12-31 | 11.22% | $1.57 Million | $13.96 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $4.92 Million | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/… Read more